ImmusanT is an early stage biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with celiac disease.
ImmusanT’s treatment is an immune tolerizing therapy using a series of peptides which target the common genetic form of celiac disease. This peptide-based immunotherapy is designed to tolerize the patient’s immune system to toxic gluten peptides.
This treatment approach to an immune disease is not unique, and there is sufficient evidence of tolerization in other disorders. ImmusanT will exploit this approach to expand development into therapies for other autoimmune disorders in the future.
ImmusanT is in a unique position, holding the relevant patents to diagnostics and treatments utilizing the gluten peptides recognized by T cells in celiac disease. No other group or company is pursuing peptide immunotherapy for celiac disease.
Research performed at The Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia, and at the University of Oxford forms the basis for the technology now being developed by ImmusanT.